Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederema.europa.eu
What's new
Get the latest updates from What's new directly as they happen.
Follow now 334 followers
Latest posts
Last updated 2 days ago
Human medicines European public assessment report (EPAR): Ondibta, insulin glargine, Date of authorisation: 09/01/2026, Revision: 3, Status: Authorised
2 days ago
Human medicines European public assessment report (EPAR): Ondibta, insulin glargine, Date of...
Human medicines European public assessment report (EPAR): Rimmyrah, ranibizumab, Date of authorisation: 05/01/2024, Revision: 6, Status: Authorised
2 days ago
Human medicines European public assessment report (EPAR): Rimmyrah, ranibizumab, Date of authorisation...
Human medicines European public assessment report (EPAR): Cenrifki, tolebrutinib, Date of authorisation: 19/06/2026, Revision: 1, Status: Authorised
2 days ago
Human medicines European public assessment report (EPAR): Cenrifki, tolebrutinib, Date of authorisation...
Human medicines European public assessment report (EPAR): Imaavy, nipocalimab, Date of authorisation: 28/11/2025, Revision: 1, Status: Authorised
2 days ago
Human medicines European public assessment report (EPAR): Imaavy, nipocalimab, Date of authorisation...
Human medicines European public assessment report (EPAR): Veoza, fezolinetant, Date of authorisation: 07/12/2023, Revision: 7, Status: Authorised
2 days ago
Human medicines European public assessment report (EPAR): Veoza, fezolinetant, Date of authorisation...
Human medicines European public assessment report (EPAR): Tuyory, tocilizumab, Date of authorisation: 27/04/2026, Revision: 2, Status: Authorised
2 days ago
Human medicines European public assessment report (EPAR): Tuyory, tocilizumab, Date of authorisation...
Human medicines European public assessment report (EPAR): Enspryng, satralizumab, Date of authorisation: 24/06/2021, Revision: 9, Status: Authorised
2 days ago
Human medicines European public assessment report (EPAR): Enspryng, satralizumab, Date of authorisation...
Orphan designation: chenodeoxycholic acid Treatment of inborn errors in primary bile acid synthesis, 16/12/2014 Positive
2 days ago
Orphan designation: chenodeoxycholic acid Treatment of inborn errors in primary bile acid...
Orphan designation: Icerguastat acetate Treatment of amyotrophic lateral sclerosis, 16/05/2022 Positive
2 days ago
Orphan designation: Icerguastat acetate Treatment of amyotrophic lateral sclerosis, 16/05/2022 Positive
Orphan designation: 2-(2-Chlorobenzylidene)hydrazinecarboximidamide acetate Treatment of Charcot-Marie-Tooth disease, 14/12/2015 Positive
2 days ago
Orphan designation: 2-(2-Chlorobenzylidene)hydrazinecarboximidamide acetate Treatment of Charcot-Marie-Tooth disease, 14/12/2015 Positive
Orphan designation: human anti-promyostatin monoclonal antibody (apitegromab) Treatment of spinal muscular atrophy, 14/12/2018 Positive
2 days ago
Orphan designation: human anti-promyostatin monoclonal antibody (apitegromab) Treatment of spinal muscular atrophy...
Human medicines European public assessment report (EPAR): Rystiggo, rozanolixizumab, Date of authorisation: 05/01/2024, Revision: 10, Status: Authorised
2 days ago
Human medicines European public assessment report (EPAR): Rystiggo, rozanolixizumab, Date of authorisation...